ITT analysis should be the primary method of analysis in cancer clinical trials, especially in phases where treatment effectiveness and safety are being evaluated under real-world conditions. It is particularly important in phase III trials, where the goal is to demonstrate the treatment's effectiveness to regulatory bodies and the medical community. However, it can be supplemented with other analyses like PP to offer a comprehensive understanding of the treatment's potential.
